CytomX Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $18.3M-86.7% YoYTTM through 30 Jun 2026
Net Income -$79.7M-349.9% YoYTTM through 30 Jun 2026
Free Cash Flow -$82.5MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| EBITDA Margin | -466.7% |
| Operating Margin | -191.8% |
| Net Margin | -435.2% |
Returns
-48.5%ROE
-25.8%ROA
Balance Sheet Health
Debt / Equity0.01x
Current Ratio10.38x
Net Debt-$346.7Mnet cash position
Cash & Equivalents$17.2M
Quality Metrics
Altman Z-Score2.44
Piotroski F-Score0 / 9
FCF Margin-450.6%
Rule of 40-413.9
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2025: $76.2M
Diluted EPSFY2025: $-0.13
Dividend
No dividend
Capital Allocation
Capex Intensity0.4%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Collaboration and License Agreements | $10.3M | -79.8% | View detailsRevenue is expected to remain highly variable and dependent on the achievement of development milestones or new strategic research expansions, such as the June 2026 expansion with Regeneron. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.